During the past decade, Neurological Research Institute conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 18 clinical trials were completed, i.e. on average, 200% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 10 clinical trials were completed. i.e. 333.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Neurological Research Institute" #1 sponsor was "JANSSEN Alzheimer Immunotherapy Research & Development, LLC" with 3 trials, followed by "Pfizer's Upjohn has merged with Mylan to form Viatris Inc." with 3 trials sponsored, "Allergan" with 2 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored and "Helixmith Co., Ltd." with 2 trials sponsored. Other sponsors include 16 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Neurological Research Institute" #1 collaborator was "Pfizer" with 3 trials as a collaborator, "CoLucid Pharmaceuticals" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Eisai Inc." with 1 trials as a collaborator and "Veristat, Inc." with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Neurological Research Institute" are "Alzheimer's Disease" (9 trials), "Migraine" (4 trials), "Painful Diabetic Neuropathy" (4 trials), "Diabetic Neuropathy, Painful" (3 trials) and "Drug Resistant Partial Onset Seizure" (2 trials). Many other conditions were trialed in "Neurological Research Institute" in a lesser frequency.

Most popular intervention types in "Neurological Research Institute" are "Drug" (30 trials), "Biological" (3 trials), "Device" (1 trials), "Genetic" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "placebo" (4 trials), "Bapineuzumab 0.5 mg/kg" (2 trials), "Bapineuzumab 1.0 m/kg" (2 trials) and "Eslicarbazepine acetate" (2 trials). Other intervention names were less common.

The vast majority of trials in "Neurological Research Institute" are 33 trials for "All" genders.

Currently, there are NaN active trials in "Neurological Research Institute". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 30 completed trials in Neurological Research Institute, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Neurological Research Institute, 0 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 22 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".